Company Long-Term Loans and Borrowings: vaxart.com (VXRT)

The Vaxart, Inc. (VXRT) market price chart reflects the dynamics of long-term liabilities, which currently stand at 0.00. The company's US centers are developing tablet-based medications for HPV and influenza, simplifying storage and delivery. The innovative VAAST gastrointestinal system creates a protected patent environment, securing Vaxart, Inc. (VXRT) as an exclusive provider. Management is focused on completing clinical trials; therefore, market confidence depends on regulatory verdicts.

VXRT Vaxart Inc. Company Long-Term Debts (07/04/2022 - 07/19/2025)

Vaxart - analytical breakdowns and key metrics (VXRT)

- market price and analyst price targets:

Stock Price Vaxart Inc.|VXRT - Price Target Chart

- company stock exchange capitalization indicators:

Market Value Vaxart|VXRT - Total Company Value

- book capitalization information:

Accounting Value per Share Vaxart|VXRT - Book Capitalization|Market Capitalization to Book Value Ratio vaxart.com|VXRT - Cumulative Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

VXRT - Company Net Income

Summary company analytics:VXRT Vaxart, Inc.

Vaxart, Inc. (VXRT) innovations in cold-chain-free oral vaccines require significant capital for clinical trials. The company's long-term debt statistics reflect the dynamics of obligations with maturities exceeding one year. This indicator measures deleveraging efficiency and the issuer's ability to service loans. A decrease in these metrics confirms financial stability during the execution of government contracts, while rising debt signals increased interest expenses and a risk of declining net income.

Competitors of Vaxart, Inc. (VXRT)